|14.37||-0.6200||-4.14%||Vol 1.65M||1Y Perf -73.03%|
|Jul 23rd, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||28.17||Analyst Rating||Strong Buy 1.00|
|Potential %||96.03||Finscreener Ranking||★★★ 49.25|
|Insiders Trans % 3/6/12 mo.||-/-91/-93||Value Ranking||★★+ 49.56|
|Insiders Value % 3/6/12 mo.||67/-97/-98||Growth Ranking||★+ 43.04|
|Insiders Shares Cnt. % 3/6/12 mo.||63/-82/-90||Income Ranking||— -|
|Market Cap||1.00B||Earnings Rating||Sell|
|Price Range Ratio 52W %||7.97||Earnings Date||9th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Aug 2021|
|Estimated EPS Next Report||-0.55|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.65M|
|Avg. Monthly Volume||3.88M|
|Avg. Quarterly Volume||4.57M|
ChemoCentryx Inc. (NASDAQ: CCXI) stock closed at 14.37 per share at the end of the most recent trading day (a -4.14% change compared to the prior day closing price) with a volume of 1.66M shares and market capitalization of 1.00B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 82 people. ChemoCentryx Inc. CEO is Thomas J. Schall.
The one-year performance of ChemoCentryx Inc. stock is -73.03%, while year-to-date (YTD) performance is -76.79%. CCXI stock has a five-year performance of 210.37%. Its 52-week range is between 9.53 and 70.29, which gives CCXI stock a 52-week price range ratio of 7.97%
ChemoCentryx Inc. currently has a PE ratio of -17.00, a price-to-book (PB) ratio of 3.06, a price-to-sale (PS) ratio of 55.97, a price to cashflow ratio of 40.20, a PEG ratio of 2.32, a ROA of -17.88%, a ROC of -24.13% and a ROE of -29.83%. The company’s profit margin is -92.18%, its EBITDA margin is -87.00%, and its revenue ttm is $19.48 Million , which makes it $0.28 revenue per share.
Of the last four earnings reports from ChemoCentryx Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. ChemoCentryx Inc.’s next earnings report date is 09th Aug 2021.
The consensus rating of Wall Street analysts for ChemoCentryx Inc. is Strong Buy (1), with a target price of $28.17, which is +96.03% compared to the current price. The earnings rating for ChemoCentryx Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ChemoCentryx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ChemoCentryx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.99, ATR14 : 1.12, CCI20 : -24.47, Chaikin Money Flow : 0.11, MACD : 0.19, Money Flow Index : 72.64, ROC : -0.69, RSI : 45.18, STOCH (14,3) : 23.68, STOCH RSI : 0.00, UO : 44.49, Williams %R : -76.32), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ChemoCentryx Inc. in the last 12-months were: Geoffrey M. Parker (Option Excercise at a value of $0), Geoffrey M. Parker (Sold 31 910 shares of value $1 806 448 ), James L. Tyree (Option Excercise at a value of $0), James L. Tyree (Sold 2 454 shares of value $23 956 ), Markus J. Cappel (Option Excercise at a value of $467 906), Markus J. Cappel (Sold 44 792 shares of value $3 052 719 ), Pui San Kwan (Option Excercise at a value of $597 169), Pui San Kwan (Sold 62 428 shares of value $4 072 485 ), Rita I. Jain (Option Excercise at a value of $0), Susan M. Kanaya (Option Excercise at a value of $0), Tausif Butt (Buy at a value of $120 241), Thomas A. Edwards (Sold 46 500 shares of value $2 856 918 ), Thomas J. Schall (Option Excercise at a value of $411 727), Thomas J. Schall (Sold 28 772 shares of value $1 870 696 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.